UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

DUSA PHARMACEUTICALS, INC.

New Jersey (State or other jurisdiction of incorporation)		0-19777 (Commission File Number)		22-3103129 (IRS Employer Identification Number)

25 Upton Drive
Wilmington, Massachusetts 01887
(Address of principal executive offices, including ZIP code)

(978) 657-7500
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02 — Results of Operations and Financial Condition.

     On May 4, 2007, DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) issued a press release, attached to and made part of this report, announcing financial results for the first quarter ended March 31, 2007.

Item 9.01 — Financial Statement and Exhibits.

Item No.		Description
99		Press Release, dated May 4, 2007

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				DUSA PHARMACEUTICALS, INC.
Dated: May 4, 2007		By:		/s/ D. Geoffrey Shulman         D. Geoffrey Shulman, MD, FRCPC
				Director, Chairman of the Board and
				Chief Executive Officer

EXHIBIT INDEX

Item No.		Description
99		Press Release, dated May 4, 2007